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Background
Microdose studies comprise the administration of a single
subpharmacological dose of a carbon-14 (14C)-labelled
drug (<100 μg) to humans in order to describe the drug's
pharmacokinetic (PK) profile in blood by means of accel-
erator mass spectrometry (AMS) analysis. As most drugs
exert their pharmacological effect in tissue rather than in
the central (blood) compartment, methodology is needed
that allows for extending PK analysis from blood to differ-
ent tissue compartments in microdose studies. In this
pilot study we combined AMS analysis with the non-inva-
sive nuclear imaging technique positron emission tomog-
raphy (PET) in order to measure the PK profile of the
model drug verapamil, at the same time in plasma and in
brain tissue. Because dose linearity of PK parameters is a
prerequisite for the prediction of therapeutic-dose from
microdose PK data, we assessed the PK parameters of ver-
apamil at two different doses.
Materials and methods
Six healthy volunteers received a microdose (0.05 mg)
and a therapeutic dose (80 mg) of verapamil, labelled
both with 14C and the positron emitter carbon-11 (11C),
in a randomised cross-over fashion. The brain distribu-
tion of verapamil was measured by means of PET imaging
whereas the drug's plasma PK was determined with AMS
analysis. PET data were analysed by kinetic modelling in
order to estimate the rate constants for the transfer of ver-
apamil across the blood-brain barrier (BBB).
Results
We were able to simultaneously measure the plasma and
brain tissue PK of verapamil by means of combined AMS
and PET analysis. Both analytical approaches suggest that
the PK of verapamil is linear over the employed dose
range (0.05–80 mg). The rate constants for BBB transfer
and the distribution volume (DV) of [11C]verapamil were
not statistically different (p > 0.10, paired t-test) for the
microdose and the therapeutic dose (K1 = 0.014 ± 0.002
ml·ml-1·min-1, k2 = 0.036 ± 0.007 min-1 and DV = 0.41 ±
0.064 for the microdose and K1 = 0.017 ± 0.0042 ml·ml-
1· min-1, k2 = 0.049 ± 0.008 min-1 and DV = 0.36 ± 0.066
for the therapeutic dose). Also, total 14C concentration-
time profiles (comprising both [14C]verapamil and its
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14C-labelled metabolites) in plasma were nearly superim-
posable after administration of both doses.
Conclusion
Combining AMS and PET analysis is a powerful approach
for gaining precise plasma and tissue PK data of drugs in
humans. The proposed set-up might be useful in the early
selection of drug candidates for further development.